NEU 2.82% $1.38 neuren pharmaceuticals limited

IGF-1 molecular pathway

  1. 1,004 Posts.
    lightbulb Created with Sketch. 123
    Treatment for neurodevelopmental and neurodegenerative conditions have proved elusive. The answer to developing effective therapeutics may be at hand.

    "Most importantly, the present data implicate the IGF-1 molecular pathway in the pathogenesis of FXS," excerpt from Abstract, NNZ-2566, a Novel Analog of (1–3) IGF-1, as a Potential Therapeutic Agent for Fragile X Syndrome co-authored by Larry Glass.

    Is it simply a case of chasing the right pathway? One problem that investigators face is distinguishing primary from secondary pathways. In CNS disease there are multiple pathways with varying degrees of interdependence. The work by Neuren has focused upon the IGF-1 molecular pathway. Success in current clinical trials could turn future research upon its head. If Neuren is successful in demonstrating the primary importance of the IGF-1 molecular  pathway, it could open the doors to a range of effective therapies.

    For instance, investigators have been chasing a cure for Alzheimer's disease by focusing upon amyloid plaque formation. It is undoubtedly a relevant target but could success be contingent upon finding a therapy to address other pathways in the disease!

    Its not a case of Tofinetide being a panacea but rather a key therapy in unlocking the complex interdependent multiple pathways in CNS disease.
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Mkt cap $141.6M
Open High Low Value Volume
$1.42 $1.42 $1.38 $45.28K 32.37K

Buyers (Bids)

No. Vol. Price($)
1 467 $1.38

Sellers (Offers)

Price($) Vol. No.
$1.42 439 1
Last update - 15.46pm 14/12/2018 (20 minute delay) ?
-0.04 ( 1.75 %)
Open High   Low Volume
$1.40 $1.40   $1.40 3300
Last updated 12.34pm 14/12/2018 (live) ?
NEU (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.